Jb Finnell
About Jb Finnell
Jb Finnell is a Talent Management and Development professional at Bristol Myers Squibb in San Diego, California, with extensive experience in clinical trial management and quality oversight.
Title
Jb Finnell holds the position of Talent Management and Development at Bristol Myers Squibb in San Diego, California, United States. His role involves strategic planning and quality oversight, ensuring the successful delivery of clinical trials and regulatory compliance.
Company
Currently, Jb Finnell is working with Bristol Myers Squibb, a leading global biopharmaceutical company. His role focuses on managing and developing talent within the organization in San Diego, California, aiming to enhance team efficiencies and achieve strategic project goals.
Previous Roles at ICON plc
Jb Finnell served as Director of Project Management at ICON plc from 2018 to 2020. During his tenure in San Diego, California, he provided leadership in managing project timelines, coordinating with stakeholders, and overseeing the successful execution of clinical development projects.
Career at Eli Lilly and Company
Jb Finnell had a significant career at Eli Lilly and Company, where he held multiple roles. As Advisor in the Medicines Quality Organization (2016-2017), he streamlined a biotech quality system. Prior to this, he was Manager of Clinical Trial Management (2011-2016) and Clinical Trial Manager (2004-2011) in Indianapolis. From 1998 to 2004, he was Regional Research Manager in the Greater Philadelphia Area, and he began as a Clinical Research Associate (1995-1998).
Education and Expertise
Jb Finnell earned a Bachelor of Science in Pharmacy from the University of Colorado at Denver and another Bachelor of Science in Chemistry from the University of Washington. His expertise includes building efficient global clinical development teams, process improvement, and ensuring high-quality delivery in clinical trials, NDA submissions, and regulatory responses.
Achievements
Jb Finnell played a pivotal role in the regulatory approval and launch of two novel drugs for critical care and cardiovascular conditions. Additionally, he successfully integrated a biotech quality system into a larger pharma quality management system, showcasing his ability to manage complex projects and improve operational efficiencies.